Literature DB >> 12379626

Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.

V Strand1, R Landéwé, D van der Heijde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379626      PMCID： PMC1766712          DOI： 10.1136/ard.61.suppl_2.ii64

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  20 in total

Review 1.  How to read radiographs according to the Sharp/van der Heijde method.

Authors:  D van der Heijde
Journal:  J Rheumatol       Date:  1999-03       Impact factor: 4.666

2.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 4.  Recent rheumatoid arthritis clinical trials using radiographic endpoints--updated research agenda.

Authors:  V Strand; M Lassere; D van der Heijde; K Johnson; M Boers
Journal:  J Rheumatol       Date:  2001-04       Impact factor: 4.666

5.  Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

Authors:  V Strand; S Cohen; M Schiff; A Weaver; R Fleischmann; G Cannon; R Fox; L Moreland; N Olsen; D Furst; J Caldwell; J Kaine; J Sharp; F Hurley; I Loew-Friedrich
Journal:  Arch Intern Med       Date:  1999-11-22

6.  Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Authors:  D L Scott; J S Smolen; J R Kalden; L B van de Putte; A Larsen; T K Kvien; M Schattenkirchner; P Nash; C Oed; I Loew-Friedrich
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

7.  A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.

Authors:  Y Jiang; H K Genant; I Watt; M Cobby; B Bresnihan; R Aitchison; D McCabe
Journal:  Arthritis Rheum       Date:  2000-05

8.  A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Authors:  P Emery; F C Breedveld; E M Lemmel; J P Kaltwasser; P T Dawes; B Gömör; F Van Den Bosch; D Nordström; O Bjorneboe; R Dahl; K Horslev-Petersen; A Rodriguez De La Serna; M Molloy; M Tikly; C Oed; R Rosenburg; I Loew-Friedrich
Journal:  Rheumatology (Oxford)       Date:  2000-06       Impact factor: 7.580

9.  Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.

Authors:  J T Sharp; V Strand; H Leung; F Hurley; I Loew-Friedrich
Journal:  Arthritis Rheum       Date:  2000-03

Review 10.  Radiography of rheumatoid arthritis in the time of increasing drug effectiveness.

Authors:  F Wolfe; V Strand
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.592
View more
  7 in total

1.  Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up.

Authors:  K Bruynesteyn; R Landewé; Sj van der Linden; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2004-03-22       Impact factor: 19.103

Review 2.  Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

Authors:  Carlomaurizio Montecucco
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study.

Authors:  Tsutomu Takeuchi; Yoshiya Tanaka; Koichi Amano; Daisuke Hoshi; Masao Nawata; Hayato Nagasawa; Eri Sato; Kazuyoshi Saito; Yuko Kaneko; Shunsuke Fukuyo; Takahiko Kurasawa; Kentaro Hanami; Hideto Kameda; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2011-07-13       Impact factor: 7.580

4.  Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial.

Authors:  H K Genant; C G Peterfy; R Westhovens; J-C Becker; R Aranda; G Vratsanos; J Teng; J M Kremer
Journal:  Ann Rheum Dis       Date:  2007-12-17       Impact factor: 19.103

5.  A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis.

Authors:  Rachel Knevel; Diederik P C de Rooy; Tore Saxne; Elisabet Lindqvist; Martha K Leijsma; Nina A Daha; Bobby P C Koeleman; Roula Tsonaka; Jeanine J Houwing-Duistermaat; Joris J M Schonkeren; Rene E M Toes; Tom W J Huizinga; Elisabeth Brouwer; Anthony G Wilson; Annette H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2014-05-07       Impact factor: 5.156

6.  PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts.

Authors:  Luis Rodriguez-Rodriguez; Jose Ivorra-Cortes; F David Carmona; Javier Martín; Alejandro Balsa; Hanna W van Steenbergen; Annette H M van der Helm-van Mil; Isidoro González-Álvaro; Benjamín Fernandez-Gutiérrez
Journal:  Arthritis Res Ther       Date:  2015-11-05       Impact factor: 5.156

7.  Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study.

Authors:  Young Bin Joo; Yul Kim; Youngho Park; Kwangwoo Kim; Jeong Ah Ryu; Seunghun Lee; So-Young Bang; Hye-Soon Lee; Gwan-Su Yi; Sang-Cheol Bae
Journal:  Arthritis Res Ther       Date:  2017-10-25       Impact factor: 5.156
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.